MBX Biosciences, Inc. (NASDAQ:MBX) Receives Consensus Rating of “Moderate Buy” from Analysts

Shares of MBX Biosciences, Inc. (NASDAQ:MBX) have received a consensus recommendation of “Moderate Buy” from the thirteen ratings firms that are currently covering the company, Marketbeat Ratings reports. Two equities research analysts have rated the stock with a sell rating, ten have assigned a buy rating and one has issued a strong buy rating on the company. The average 1-year target price among brokerages that have updated their coverage on the stock in the last year is $60.2222.

A number of equities analysts recently commented on the stock. Lifesci Capital raised shares of MBX Biosciences to a “strong-buy” rating in a research report on Tuesday, March 31st. Citizens Jmp boosted their price objective on shares of MBX Biosciences from $76.00 to $86.00 and gave the company a “market outperform” rating in a report on Tuesday, May 12th. Weiss Ratings restated a “sell (d-)” rating on shares of MBX Biosciences in a research report on Tuesday, April 21st. Stifel Nicolaus set a $56.00 target price on shares of MBX Biosciences in a report on Tuesday, May 12th. Finally, Barclays lifted their price target on shares of MBX Biosciences from $66.00 to $70.00 and gave the company an “overweight” rating in a research report on Tuesday, May 12th.

MBX Biosciences Stock Performance

MBX opened at $57.80 on Friday. The stock has a fifty day moving average of $37.28 and a 200-day moving average of $34.75. The company has a market capitalization of $2.75 billion, a P/E ratio of -26.15 and a beta of 0.16. MBX Biosciences has a fifty-two week low of $9.63 and a fifty-two week high of $58.50.

Hedge Funds Weigh In On MBX Biosciences

A number of hedge funds have recently added to or reduced their stakes in the stock. Hudson Bay Capital Management LP acquired a new stake in MBX Biosciences during the third quarter worth about $1,488,000. Ghisallo Capital Management LLC acquired a new position in shares of MBX Biosciences in the 3rd quarter valued at approximately $669,000. Aaron Wealth Advisors LLC raised its position in shares of MBX Biosciences by 40.0% in the 4th quarter. Aaron Wealth Advisors LLC now owns 70,000 shares of the company’s stock valued at $2,208,000 after buying an additional 20,000 shares in the last quarter. Goelzer Investment Management Inc. bought a new stake in shares of MBX Biosciences during the 4th quarter worth approximately $6,992,000. Finally, Baker BROS. Advisors LP bought a new stake in shares of MBX Biosciences during the 3rd quarter worth approximately $4,861,000.

About MBX Biosciences

We are a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders. Our company was founded by global leaders with a transformative approach to peptide drug design and development. Leveraging this expertise, we designed our proprietary Precision Endocrine Peptide™, or PEPTM, platform to overcome the key limitations of unmodified and modified peptide therapies and to improve clinical outcomes and simplify disease management for patients.